

Regentis Biomaterials Announces First Patient Treated in its Cartilage Clinical Study

Regentis Biomaterials announced today that the first patient has been successfully operated in its' Cartilage Clinical Study. The study a single arm, open label, multi-center study to evaluate the safety and performance of articular cartilage lesions located on the femoral condyle, with the company's proprietary tissue repair matrix, **GelrinC**. The procedure was performed by Sven Anders, MD, at Regensburg University Hospital, Regensburg, Germany.

GelrinC is a biodegradable, of-the-shelf, a-cellular implant made of polyethylene glycol diacrylate (PEG-DA) covalently conjugated with a structural backbone of denatured fibrinogen chains. The device comes in a liquid form, injected into the lesion site and polymerized in situ into a stable hydrogel solid matrix. The device gradually degrades over a period of 6-12 months whilst enabling natural functional tissue to fill the space occupied previously by the implant.

The first patient was had a single lesion on his femoral condyle. The lesion was successfully treated with **GelrinC**. The patient was discharged from the hospital and is doing well.

"We are pleased Dr. Anders has successfully implanted **GelrinC** in the patient lesion, this is a key milestone for the company in its path to prove safety and efficacy of **GelrinC** as a treatment for cartilage repair" said Yehiel Tal, the company's CEO, "We believe that Regentis technology platform **GelrinC** offers a significant therapeutic advantage to patients with local cartilage lesions"

About Regentis Biomaterials:

Established in 2004, Regentis Biomaterials is a tissue repair company that is developing and commercializing innovative biodegradable hydrogels for the local repair of damaged cartilage and bone. Our platform technology is a family of hydrogels called **Gelrin™**. These gels can be injected or applied to a specific local site and offer beneficial properties for the local repair of damaged tissue such as cartilage and bone.

The **Gelrin™** technology offers off-the-shelf products that are designed to be suitable for both open surgery and minimally invasive procedures. An ideal solution for physicians and their patients, the products are easy to implant and have been shown to stimulate the regeneration of healthy cartilage and bone tissue. Regentis' first orthopedic product is **GelrinC**, a biodegradable hydrogel for articular cartilage regeneration. Additional pipeline products include **GelrinB** - a biodegradable hydrogel for bone regeneration; and **GelrinA** - a void filling matrix for aesthetic indications.

CAUTION: **GelrinC** is an investigational product, not available in Europe and in the US